ClinConnect ClinConnect Logo
Search / Trial NCT04814095

PRecision Oncology Evidence Development in Cancer Treatment - Clinical: PREDiCTc

Launched by BRITISH COLUMBIA CANCER AGENCY · Mar 22, 2021

Trial Information

Current as of August 20, 2025

Recruiting

Keywords

Targeted Therapy Health Technology Assessment Real World Evidence Quality Of Life

ClinConnect Summary

The PREDiCTc trial is studying how well a specific type of targeted therapy works for patients with advanced rare cancers or those who have unique genetic changes in their tumors. This therapy has already been approved by Health Canada as safe and effective, but because these cancers are rare, it's not currently funded by national health programs. The goal of this trial is to gather real-world evidence about how this treatment affects patients' quality of life and survival, which can help in future funding decisions.

To participate in this trial, you need to be at least 18 years old and have a cancer diagnosis that is considered incurable, specifically a rare type or with rare genetic changes. You should also be receiving a Health Canada-approved targeted therapy that isn't nationally funded. Participants should have a life expectancy of at least 12 weeks and be able to complete questionnaires about their quality of life. Throughout the study, participants will share their experiences, which will contribute important information to help others in the future.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Subject age greater than or equal to 18 years at the time of signature of informed consent.
  • Subjects with an incurable malignancy who have been identified to have a rare cancer or rare molecular aberration who is currently receiving Health Canada approved targeted therapy that is not nationally funded
  • ECOG 0-2
  • Life expectancy of at least 12 weeks
  • Adequate hematologic and end organ function for drug treatment per the clinician's assessment
  • Asymptomatic or treated brain metastases permitted
  • Ability to give informed consent for the study procedures defined in this protocol.
  • Exclusion Criteria:
  • Treatment with any approved or investigational agent or participation in another clinical trial with therapeutic intent within 14 days prior to enrollment.
  • Inability to complete quality of life questionnaires
  • Subjects who are felt by the treating clinician to be unfit to proceed with this protocol.

About British Columbia Cancer Agency

The British Columbia Cancer Agency (BCCA) is a leading organization dedicated to cancer research, treatment, and prevention in Canada. As a prominent clinical trial sponsor, BCCA focuses on advancing cancer care through innovative research and the development of new therapeutic strategies. With a commitment to improving patient outcomes, BCCA collaborates with a network of healthcare professionals and research institutions to conduct rigorous clinical trials that explore cutting-edge treatments and diagnostic methods. Their multidisciplinary approach, combined with a strong emphasis on patient-centered care, positions BCCA at the forefront of cancer research and healthcare advancements.

Locations

Vancouver, British Columbia, Canada

Patients applied

0 patients applied

Trial Officials

Cheryl Ho, MD

Principal Investigator

BC Cancer

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials